HEAD OF MENTAL HEALTH
INSTITUTE LEAVING FOR GOOGLE
LIFE SCIENCES
In this New York Times article,
Benedict Cary explores the impact Dr.
Thomas R. Insel's departure from the
National Institute of Mental Health after
a13-year tenure to join Google Life
Sciences will have on behaviorial sciences
in the US.
* Read more here:
http://www.nytimes.com/2015/09/16/health/
tom-insel-national-institute-of-mental-
health-resign.html?_r=1
IN ITS FIRST YEAR, HAS APPLE'S
RESEARCHKIT REVOLUTIONIZED
MEDICAL RESEARCH?
Here, in a Fast Company article,
Christina Farr discusses Apple's recently
launched initiative ResearchKit, its first
service for medical researchers to develop
iPhone-based studies. These apps are
currently being used to study a variety of
ailments, including diabetes, breast cancer,
asthma, and heart disease. ResearchKit, an
open-source framework, is primarily
intended for use by developers at major
academic hospitals and universities to help
make patient recruitment for clinical trials
easier and cheaper. Ms. Farr interviews
developers, entrepreneurs, and researchers
to find out whether Apple's much-hyped
ResearchKit has lived up to its promise of
revolutionizing medical research.
* Read more here:
http://www.fastcompany.com/3058125/in-
its-first-year-has-apples-researchkit-
revolutionized-medical-
research?utm_content=bufferb4b5b&utm;_
medium=social&utm;_source=twitter.com&
utm_campaign=buffer
23andME TECH BRINGS GENETIC
DATA TO APPLE RESEARCHKIT
STUDIES
According to FierceBiotech, the
makers of the genetic spit test, 23andMe,
have moved to integrate the genetic data
they generate from these tests into
studies run on Apple's ($AAPL)
ResearchKit framework. The move,
which takes the form of a ResearchKit
module, is intended to enable 23andMe
customers to contribute their results to
research programs, while also making it
easier for the organizers of studies to
generate genetic data.
* Read more here:
http://www.fiercebiotechit.com/story/23a
ndme-tech-brings-genetic-data-apple-
researchkit-studies/2016-03-
28?utm_content=bufferf3868&utm;_medi
um=social&utm;_source=twitter.com&ut;
m_campaign=buffer
WHAT IS PERSONALIZED
MEDICINE?
Personalize medicine is changing the
world of healthcare. This article by Dawn
McMullen, published in Genome, tells
you what you need to know about the
personalized medicine movement fueled
by genomic testing and tailored
treatment--Certainly this will have a huge
impact on how drugs are developed.
* Read more here:
http://genomemag.com/what-is-
personalized-medicine/#.Vv6pBj9zLqS
ACADEMIA AND INDUSTRY DO
NOT NEED TO BE AT ODDS WITH
EACH OTHER
Here, David Shaywitz via Forbes
Magazine tackles the pervasive negative
publicity pharma companies have been
getting lately in the media, and describes
the vital role these companies play in
translating fragile but promising scientific
ideas into robust medicines for patients.
According to Mr. Shaywitz, "We should
encourage innovative partnerships that
bridge the translational divide, and
inspire more journalists to capture the
value of this difficult and ambitious
mission."
* Read more here:
http://www.forbes.com/sites/davidshaywit
z/2016/04/04/the-vital-role-of-industry-in-
crossing-the-translational-
divide/?utm_content=buffer2c1ca&utm;_
medium=social&utm;_source=twitter.com
&utm;_campaign=buffer#7b20c7f2287f
DATA QUALITY MONITORING IN
CLINICAL TRIALS: HAS IT BEEN
WORTH IT? AN EVALUATION AND
PREDICTION OF THE FUTURE BY
ALL STAKEHOLDERS
This paper summarizes the results of
the CNS Summit Data Quality Monitoring
Workgroup analysis of current data
quality monitoring techniques used in
central nervous system (CNS) clinical
trials. Perspectives of pharmaceutical
companies and trial sites regarding data
quality monitoring are presented.
Potential future developments in CNS
data quality monitoring are described.
* Read more here:
http://innovationscns.com/data-quality-
monitoring-in-clinical-trials-has-it-been-
worth-it-an-evaluation-and-prediction-of-
the-future-by-all-stakeholders/
Hot Topics in Drug Development [April 2016]
7